搜索
Tempest Therapeutics Inc
TPST添加自选
0.496USD
-0.037-6.94%
收盘 10-30 16:00（美东）
8.38M总市值
0.02市盈率 TTM
盘后交易 16:33 (美东)0.502USD-0.002-0.40%
盘后交易 16:33 (美东)关于 Tempest Therapeutics Inc 公司
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
Tempest Therapeutics Inc 简介
公司代码TPST
公司名称Tempest Therapeutics Inc
上市日期Oct 04, 2012
CEO- -
员工数量24
证券类型Ordinary Share
年结日Oct 04
公司地址2000 Sierra Point Parkway
城市BRISBANE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编94005
电话14157988589
网址https://www.tempesttx.com/
公司代码TPST
上市日期Oct 04, 2012
CEO- -
Tempest Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Matthew (Matt) Angel, Ph.D.
Dr. Matthew (Matt) Angel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
5.07M
--
Dr. Matthew (Matt) Angel, Ph.D.
Dr. Matthew (Matt) Angel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
5.07M
--
Mr. Stephen R. Brady
Mr. Stephen R. Brady
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
3.61K
--
Dr. Geoffrey M. (Geoff) Nichol
Dr. Geoffrey M. (Geoff) Nichol
Independent Director
Independent Director
666.00
--
Mr. Nicholas Maestas
Mr. Nicholas Maestas
Principal Financial Officer
Principal Financial Officer
590.00
--
Dr. Samuel (Sam) Whiting, M.D., Ph.D.
Dr. Samuel (Sam) Whiting, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
-100.00%
Dr. John David Yee, M.D.
Dr. John David Yee, M.D.
Independent Director
Independent Director
--
--
Mr. William Drake Richey
Mr. William Drake Richey
Independent Director
Independent Director
--
--
Ms. Nancy Freda-Smith, CPA
Ms. Nancy Freda-Smith, CPA
Director
Director
--
--
Constance Ames
Constance Ames
Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, Corporate Secretary
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Matthew (Matt) Angel, Ph.D.
Dr. Matthew (Matt) Angel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
5.07M
--
Dr. Matthew (Matt) Angel, Ph.D.
Dr. Matthew (Matt) Angel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
5.07M
--
Mr. Stephen R. Brady
Mr. Stephen R. Brady
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
3.61K
--
Dr. Geoffrey M. (Geoff) Nichol
Dr. Geoffrey M. (Geoff) Nichol
Independent Director
Independent Director
666.00
--
Mr. Nicholas Maestas
Mr. Nicholas Maestas
Principal Financial Officer
Principal Financial Officer
590.00
--
Dr. Samuel (Sam) Whiting, M.D., Ph.D.
Dr. Samuel (Sam) Whiting, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
-100.00%
常见问题
Tempest Therapeutics Inc的前五大股东是谁？
Tempest Therapeutics Inc 的前五大股东如下：Dr. Matthew (Matt) Angel, Ph.D.
有多少机构持有Tempest Therapeutics Inc(TPST)的股份？
截至2026Q1，共有68家机构持有Tempest Therapeutics Inc的股份，合计持有的股份价值约为4.51M，占公司总股份的31.43%。与2025Q4相比，机构持股有所增加，增幅为3582210.00。